摘要:
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.
摘要:
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.
摘要:
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.
摘要:
CpG densities and sequence motifs that are characteristic of regions of DNA associated with epimutations and control of epimutations are provided. Such regions include, within approximately 400 (or fewer) base pairs, at least one, usually two, and preferably all three of the following features: i) a CpG density of 15% or less; ii) the presence of the sequence motif ATTTGTTTTTTCTTTTnT (SEQ ID NO: 1) where n is A, T, C or G, and statistically relevant variants thereof; and iii) the presence of the sequence motif GGGGGnGGGG (SEQ ID NO: 2), where n is A, T, C or G, and statistically relevant variants thereof.
摘要翻译:提供了与突变相关的DNA区域和突变的控制特征的CpG密度和序列基序。 这样的区域包括在约400个(或更少)碱基对内,至少一个,通常两个,优选全部三个以下特征:i)CpG密度为15%或更小; ii)序列基序ATTTGTTTTTTCTTTTnT(SEQ ID NO:1)的存在,其中n是A,T,C或G,以及其统计学上相关的变体; 和iii)序列基序GGGGGnGGGG(SEQ ID NO:2)的存在,其中n是A,T,C或G,以及其统计学上相关的变体。
摘要:
CpG densities and sequence motifs that are characteristic of regions of DNA associated with epimutations and control of epimutations are provided. Such regions include, within approximately 400 (or fewer) base pairs, at least one, usually two, and preferably all three of the following features: i) a CpG density of 15% or less; ii) the presence of the sequence motif ATTTGTTTTTTCTTTTnT (SEQ ID NO: 1) where n is A, T, C or G, and statistically relevant variants thereof; and iii) the presence of the sequence motif GGGGGnGGGG (SEQ ID NO: 2), where n is A, T, C or G, and statistically relevant variants thereof.
摘要:
A two-step (sequential) machine learning analysis tool is provided that involves a combination of an initial active learning step followed by an imbalance class learner (ACL-ICL) protocol. This technique provides a more tightly integrated approach for a more efficient and accurate machine learning analysis. The combination of ACL and ICL work synergistically to improve the accuracy and efficiency of machine learning and can be used with any type of dataset including biological datasets.
摘要:
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.
摘要:
Provided herein are methods and kits for providing a likelihood of fertility in a subject. Further, provided herein are methods and kits for determining whether a subject responds to a fertility treatment.
摘要:
The present disclosure relates to methods of analyzing epigenetic alterations in the germline DNA of animals. More particularly, the present disclosure relates to methods of analyzing histone retention involved in epigenetic alterations as well as the identification and treatment of diseases associated with such epigenetic alterations.